CNC vs. HUM, MOH, ELV, IDXX, ALC, MRNA, GEHC, TAK, HLN, and IQV
Should you be buying Centene stock or one of its competitors? The main competitors of Centene include Humana (HUM), Molina Healthcare (MOH), Elevance Health (ELV), IDEXX Laboratories (IDXX), Alcon (ALC), Moderna (MRNA), GE HealthCare Technologies (GEHC), Takeda Pharmaceutical (TAK), Haleon (HLN), and IQVIA (IQV). These companies are all part of the "medical" sector.
Humana (NYSE:HUM) and Centene (NYSE:CNC) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, community ranking, media sentiment and dividends.
92.4% of Humana shares are owned by institutional investors. Comparatively, 93.6% of Centene shares are owned by institutional investors. 0.3% of Humana shares are owned by company insiders. Comparatively, 0.3% of Centene shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Centene has higher revenue and earnings than Humana. Centene is trading at a lower price-to-earnings ratio than Humana, indicating that it is currently the more affordable of the two stocks.
Centene received 128 more outperform votes than Humana when rated by MarketBeat users. Likewise, 73.24% of users gave Centene an outperform vote while only 64.19% of users gave Humana an outperform vote.
In the previous week, Humana had 33 more articles in the media than Centene. MarketBeat recorded 42 mentions for Humana and 9 mentions for Centene. Humana's average media sentiment score of 0.88 beat Centene's score of 0.40 indicating that Centene is being referred to more favorably in the news media.
Humana has a net margin of 2.34% compared to Humana's net margin of 1.75%. Centene's return on equity of 19.44% beat Humana's return on equity.
Humana currently has a consensus price target of $454.63, suggesting a potential upside of 43.88%. Centene has a consensus price target of $85.38, suggesting a potential upside of 12.07%. Given Centene's higher probable upside, analysts clearly believe Humana is more favorable than Centene.
Humana has a beta of 0.45, suggesting that its share price is 55% less volatile than the S&P 500. Comparatively, Centene has a beta of 0.38, suggesting that its share price is 62% less volatile than the S&P 500.
Summary
Humana beats Centene on 10 of the 17 factors compared between the two stocks.
Get Centene News Delivered to You Automatically
Sign up to receive the latest news and ratings for CNC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CNC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
